Sarepta Therapeutics (NASDAQ: SRPT) reported Q3 EPS of ($0.13), $0.57 better than the analyst estimate of ($0.70). Revenue for the quarter came in at $399.4 million versus the consensus estimate of $337.91 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.